ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 97 filers reported holding ALX ONCOLOGY HLDGS INC in Q1 2022. The put-call ratio across all filers is 0.84 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,600,718 | -12.2% | 333,483 | +37.3% | 0.00% | – |
| Q2 2023 | $1,823,774 | +28.4% | 242,846 | -22.7% | 0.00% | – |
| Q1 2023 | $1,420,123 | -74.1% | 314,186 | -35.4% | 0.00% | -100.0% |
| Q4 2022 | $5,480,803 | +44.4% | 486,318 | +22.6% | 0.00% | 0.0% |
| Q3 2022 | $3,796,000 | +5.7% | 396,637 | -10.7% | 0.00% | – |
| Q2 2022 | $3,592,000 | -44.7% | 443,935 | +15.5% | 0.00% | -100.0% |
| Q1 2022 | $6,497,000 | +18.7% | 384,518 | +51.0% | 0.00% | 0.0% |
| Q4 2021 | $5,473,000 | -9.0% | 254,700 | +212.8% | 0.00% | 0.0% |
| Q3 2021 | $6,014,000 | +8.9% | 81,420 | -19.4% | 0.00% | 0.0% |
| Q2 2021 | $5,523,000 | +1543.8% | 101,009 | +2116.6% | 0.00% | – |
| Q1 2021 | $336,000 | -69.0% | 4,557 | -63.7% | 0.00% | – |
| Q4 2020 | $1,083,000 | +1404.2% | 12,564 | +561.6% | 0.00% | – |
| Q3 2020 | $72,000 | – | 1,899 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $716,436,000 | 71.38% |
| Logos Global Management LP | 3,156,981 | $233,175,000 | 16.81% |
| Vivo Capital, LLC | 4,220,048 | $311,693,000 | 14.00% |
| Cormorant Asset Management, LP | 1,012,079 | $74,752,000 | 3.04% |
| Redmile Group, LLC | 864,435 | $63,847,000 | 1.11% |
| Nan Fung Group Holdings Ltd | 41,950 | $3,098,000 | 0.99% |
| Artal Group S.A. | 500,000 | $36,930,000 | 0.83% |
| SPHERA FUNDS MANAGEMENT LTD. | 128,706 | $9,506,000 | 0.80% |
| Pier Capital, LLC | 75,362 | $5,566,000 | 0.58% |
| Financial Advisory Group | 31,417 | $2,320,000 | 0.51% |